alumis-inc-faces-downward-market-trend-amid-zero-revenue
Legacy AI Deep Dive Analysis of Alumis Inc. Common Stock (ALMS)
The article mentions various stocks and their current values. Some of the stocks listed are Alumis Inc, BioSig Technologies Inc, Capstone Holding Corp, Cyclo Therapeutics Inc, GlucoTrack Inc, Inspire Veterinary Partners Inc, Know Labs Inc, Mural Oncology PLC, Orchestra BioMed Holdings Inc, Predictive Oncology Inc, Palatin Technologies Inc, and Tenon Medical Inc. The prices and percentages of change in their values are also provided.
Alumis has reported robust financial results for the year 2024, showing significant progress in its late-stage pipeline of oral TYK2 inhibitors for diseases related to the immune system. Additionally, the company has announced a merger with ACELYRIN, which will result in a combined entity boasting a differentiated portfolio and enhanced financial flexibility.
1) Brief Summary: Alumis Inc., a pharmaceutical company, is currently experiencing a downward trend in the market with a -60.41% SMA200 and -33.18% SMA50. The company's short float of 11.63% indicates a significant level of short interest. The firm's sales growth over the past five years is zero, and there was a negative EPS surprise of -24.94%. The firm's debt-to-equity ratio is quite low at 0.12, suggesting minimal risk from debt. However, the firm's ROE and ROI are both in the negative, implying poor profitability. Recent insider trading shows key personnel exercising their right to buy significant shares, indicating their confidence in the company's future. However, the company has reported no revenues and a net loss in its latest financial statements.
2) MARKET_SCORE: 30
: Given the current bearish trend and financial performance, the likelihood of an upward move in the near term is estimated at 30%. 3) PRICE_TARGET: $4.00
: Considering the current downward trend, a conservative price target would be a modest increase from the latest closing price of $3.775 to $4.00. 4) AI_RPT_HEADLINE: "Alumis Inc. Faces Downward Market Trend Amid Zero Revenue".
: Given the current bearish trend and financial performance, the likelihood of an upward move in the near term is estimated at 30%. 3) PRICE_TARGET: $4.00
: Considering the current downward trend, a conservative price target would be a modest increase from the latest closing price of $3.775 to $4.00. 4) AI_RPT_HEADLINE: "Alumis Inc. Faces Downward Market Trend Amid Zero Revenue".
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
======================================================
: 2025-03-25 05:39:52
# Analysis Completed Elapsed Time: 49.26 seconds
# Analysis Completed Elapsed Time: 49.26 seconds
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment. This particular report predates the BPE and is here for historic value.